“The vaccine will be available to our first line of defense heroes who are at the highest threat of contracting the virus,” the National Emergency Crisis and Disaster Management Authority (NCEMA) tweeted monday.
Chinese pharmaceutical giant Sinopharm began the third phase of COVID-19 vaccine trials in the United Arab Emirates in July, and Emirati officials said the effects were positive.
“Clinical trials in the 3rd phase continue under the strict supervision of medical equipment, while all measures for the quality, protection and efficacy of the vaccine are followed,” NCEMA said.
“The effects of clinical trials in our country are on the right track, and all the tests have been a success so far. “
NCEMA said the vaccine verified 31,000 volunteers and only “mild and expected” side effects were reported, adding that 1,000 control subjects with chronic diseases showed no “complications. “
Monday’s announcement came amid an increase in coronavirus instances in the United Arab Emirates, the death toll of which hit an all-time high on Saturday when the country recorded 1,007 infections.
The Gulf State has shown more than 80,000 cases in total, 401 deaths.
Sinopharm said he expected his vaccine to be approved until the end of the year.
He predicts that the antibodies in his vaccine can last between one and three years, the end result will not be known until after trials.
Lately, there are nine vaccine applicants in the final phase of human trials around the world, some have encountered recent obstacles: pharmaceutical giant AstraZeneca and Oxford University temporarily suspended clinical trials last week after a volunteer developed an unexplained disease.
Meanwhile, Russia announced last month that its vaccine, called “Sputnik V” in honor of the Soviet-era satellite that was first introduced to the area in 1957, had already been approved.